Metabolic syndrome: Maladaptation to a modern world

Journal of the Royal Society of Medicine

Volumn 97, Issue 11, 2004, Pages 511-520

  Wilkin, Terence J ^a   Voss, Linda D ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; C REACTIVE PROTEIN; CORTICOTROPIN; HYDROCORTISONE; INSULIN; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRIACYLGLYCEROL;

ANTHROPOMETRIC PARAMETERS; BLOOD PRESSURE REGULATION; BODY FAT; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CORTICOTROPIN RELEASE; DIABETIC ANGIOPATHY; DRUG MECHANISM; ENERGY EXPENDITURE; EXERCISE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEALTH CARE POLICY; HIGH RISK PATIENT; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; OVERNUTRITION; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREECLAMPSIA; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; STEIN LEVENTHAL SYNDROME; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 8744254403     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.97.11.511     Document Type: Review

References (83)

1. Reaven GM. The role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
2. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997;53:238-52
3. Prentice AM. Epidemiology and health risks of obesity. Topical Endocrinol 1997;6:2-4
4. Quetelet MA. ATreatise on Man and the Development of his Faculties. Edinburgh: Chambers, 1842:63-7
5. Loutan L, Lamotte JM. Seasonal variations in nutrition among a group of nomadic pastoralists in Niger. Lancet 1984;i:945-7
6. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000;247:301-10
7. Illich I. Medical Nemesis. Lancet 1974;i:918-21
8. Shakespeare W. Henry IV, Part 1, Act II, scene iv
9. Britz B, Siegfried W, Ziegler A, et al. Rates of psychiatric disorders in a clinical study group of adolescents with extreme obesity and in obese adolescents ascertained via a population based study. Int J Obesity Rel Metabol Disord 2000;24:1707-14
10. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6
11. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-9
12. Wilkin TJ. Endocrine feedback control in health and disease. In: Bittar EE, Bittar N, eds. The Principles of Medical Biology. Greenwich, CT: JAI Press, 1998, 1-28
13. Himsworth HP. Diabetes: its differentiation into insulin sensitive and insulin insensitive. Lancet 1936;i:127-30
14. Day D. Population-based screening with the Coronary Heart Disease Risk Factor Calculator. Adv Ther 2001;18:21-32
15. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-9
16. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506
17. Enzi G, Busetto L, Carraro R. Association of multiple risk factors for cardiovascular disease and visceral obesity. A deadly quartet or sextet? In: Ditshunheit H, et al., eds. Obesity in Europe. London: Libbey, 1994:411-18
18. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 1996;44:277-84
19. Agarwal SK, Judd HL, Magoffin DA. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3686-91
20. Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710-5
21. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562-8
22. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8
23. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
24. Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003;88:2393-8
25. Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003;46:595-607.
26. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004;96:1152-60
27. Norman RJ, McVeigh E. Polycystic ovary syndrome and implications for the menopause. Climacteric 1999;2:141-3
28. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004;65:634-51
29. Vague J. The degree of masculine differentiation in obesity as a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 1956;4:20-34
30. Voss LD, Metcalf BS, Jeffery AN, et al. Preventable factors in childhood that lead to insulin resistance, diabetes mellitus and the metabolic syndrome: the EarlyBird Diabetes Study (1). J Pediatr Endocr Metab 2003;16:1211-24
31. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999;2:37-44
32. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56
33. Pantanetti P, Garrapa GG, Mantero F, Boscaro M, Faloia E, Venarucci D. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens 2004;26:387-98
34. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004;13:215-23
35. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511-25
36. Diez JJ, Iglesis P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinology 2003;148:293-300
37. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83
38. Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 2002;87:4652-6
39. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-10
40. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-63
41. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80
42. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002;51:314-7
43. Park KG, Park KS, Kim MJ, et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 2004;63:135-42
44. Machann J, Haring H, Schick F, Stumvoll M. Intramyocellular lipids and insulin resistance. Diabetes Obes Metab 2004;6:239-48
45. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3-20
46. Bjorntorp P, Rosmond R. The metabolic syndrome-a neuroendocrine disorder? Br J Nutr 2000;83 Suppl 1:S49-57
47. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633-8
48. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-6
49. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20
50. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73: 460-8
51. Lemieux S, Prud'homme D, Tremblay A, Bouchard C, Després JP. Anthropometric correlates to changes in visceral adipose tissue over 7 years in women. Int J Obes Relat Metab Disord 1996;20:618-24
52. Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP. Type 2 diabetes in obese white children. Arch Dis Child 2002;86:207-8
53. Aye T, Levitsky LL. Type 2 diabetes: an epidemic disease in childhood. Curr Opin Pediatr 2003;15:411-15
54. Hales CN, Barker DJ, Clark PM, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991;303:019-22
55. Barker DJ. In utero programming of chronic disease. Clin Sci (Lond) 1998;95:115-28
56. Lucas A, Fewtrell MS, Cole TJ. Fetal origins of adult disease-the hypothesis revisited. BMJ 1999;319:245-9
57. Wilkin TJ, Metcalf BS, Murphy MJ, Kirkby J, Jeffery AN, Voss LD. The relative contributions of birth weight, weight change, and current weight to insulin resistance in contemporary 5-year-olds: the EarlyBird Study. Diabetes 2002;51:3468-72
58. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase of type 1 diabetes-analysis of the data on published incidence trends. Diabetologia 1999;42:1395-403
59. Wilkin TJ. The Accelerator Hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001;44:914-22
60. Baum JD, Ounsted M, Smith MA. Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet 1975;ii:866
61. Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK. Obesity, increased linear growth, and risk of type 1 diabetes in children. Childhood Diabetes in Finland Study Group. Diabetes Care 2000;23:1755-60
62. Kibirige M, Metcalf BS, Mallam K, Renuka R, Wilkin TJ. Testing the Accelerator Hypothesis (1): The relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003;26:2865-70
63. Betts P, Mulligan J, Ward P, Smith B, Wilkin TJ. Increasing body weight predicts the earlier onset of insulin dependant diabetes in childhood: testing the 'Accelerator Hypothesis' (2). Diabetic Med (in press)
64. Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes-indication of an increased environmental pressure? Diabetologia 2003;46:420-S
65. Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 2001;107:E102
66. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15 suppl 1:525-30
67. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7
68. Wilkin T, Ludvigsson J, Greenbaum C, Palmer J, Becker D, Bruining J. Future intervention trials in type 1 diabetes. Diabetes Care 2004;27:996-7
69. Shafrir E, Raz I. Diabetes: mellitus or lipidus? Diabetologia 2003;46:433-40
70. [http://www.nice.org.uk/pdf/NICE_INHERITEG_guidelines.pdf]
71. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC.UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303
72. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002;20:1873-8
73. Fleischmann EH, Friedrich A, Danzer E, Gallert K, Walter H, Schmieder RE: Intensive training of patients with hypertension is effective in modifying lifestyle risk factors. J Hum Hypenens 2004;18:127-31
74. Shargorodsky M, Wainstein J, Gavish D, et al. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003;16:617-22
75. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
76. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
77. Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. Am J Clin Nutr 2004;80:308-16
78. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-94
79. Camejo G, Ljung B, Oakes N. Pharmacological treatment of insulin resistance in obesity. Nutr Metab Cardiovasc Dis 2001;11:275-84
80. Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003;149:323-9
81. Vrbikova J, Cibula D, Dvorakova K, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:2942-5
82. Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004;115:125-33
83. Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J Pediatr Endocrinol Metab 2001;14: 1085-91